Sick enough: the silent struggles of sub-clinical illness in modern medicine
To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.
Biotech & Life Sciences
In the Company of Shadows: Love, Labour, and the Long Way Through
First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.
Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care
Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.
The rise of Chinese pharmaceuticals and biotech
"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.
More than just a headache
“Pain is treated like a badge of honor" in medicine, but the cost is a workforce breaking under invisible pressure.
Artificial intelligence in skin cancer diagnosis: Improving diagnostics and reducing health disparity
"AI has already been shown to be just as, if not more, accurate than dermatologists," Dr. Alexander Green explains, as DERM proves 99.8% effective at ruling out cancer.
Martial law targets resident physicians: implications for the healthcare crisis in South Korea
Industrial relations between doctors and the state have never been worse
The future of fluorescence is smaller, smarter, and more accessible
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
How Piramal Pharma plans to become a multi-billion dollar business
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
We all want our hospital records in one place. Is Novellia the app to do it?
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Backed by AstraZeneca, this company is helping radioligand cancer therapies hit the shelves
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
CAR-T can only treat 3% of cancer patients. Mongoose Bio is building for the other 97%
Neil Warma explains how Mongoose Bio is pioneering TCR-T therapies that may last longer, tackle more cancers, and require less from patients.
This biotech is targeting the 'immortality switch' to fight blood cancers
Harnessing Nobel Prize-winning insights on telomeres, Geron’s CEO Dr. John A. Scarlett is taking on some of hematology’s toughest challenges—and winning FDA backing in the process.
NVIDIA’s Biggest Bet Yet: How Recursion Is Powering a New Era of AI-Driven Drug Discovery
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases
A Grammy-winning CEO is taking gene therapy to new heights.